Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Risk Profile Improvements

  • Going Concern (worsened) — Substantial doubt persists given cash of only $0.1M and operating cash outflow of $2.3M against minimal liquidity; the reported $154.3M net loss is overwhelmingly non-cash (Business Combination charges), not cash burn.
  • Material Weakness (unchanged) — Material weaknesses in internal controls over carve-out financial statement preparation and stock-based compensation remain disclosed with no remediation completion.
  • Controlled Company (unchanged) — Controlled-company structure persists from prior filing; no change disclosed in control dynamics.
  • Cryptocurrency Treasury Strategy (new) — Filing maintains a standing Risks Related to Cryptocurrency disclosure for a named Bitcoin treasury/financing strategy that has not been implemented or tested (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material even when a related financing line moves out of Recent Developments.
OTC: SMNR Semnur Pharmaceuticals, Inc. S-1/A

Semnur starts 2nd Phase 3 study as cash falls to $0.1M; $154M net loss driven by non-cash charges

Filed December 19, 2025 · Compared to S-1 Oct 21, 2025 · ~1 min read

IPO filing cluster

Same offering
  1. S-1 Oct 21, 2025 Semnur Pharmaceuticals secondary offering by selling stockholders; company receives no proceeds EDGAR →
  2. S-1/A Dec 19, 2025 This filing EDGAR →
  3. 424B3 Dec 29, 2025 Semnur Pharmaceuticals selling securityholders offer up to 12.85M warrants; company receives no proceeds from resale EDGAR →
  4. 424B3 Jun 15, 2026 No report yet EDGAR →
  5. 8-K Jun 25, 2026 No report yet EDGAR →

Key Changes

  • high

    Net loss of $154.3M in nine months ended Sep 2025 vs operating cash outflow of only $2.3M — the gap is overwhelmingly non-cash charges (SPAC merger costs, stock comp, fair-value adjustments), not cash burned through operations.

    MD&A: Operating Losses verify on EDGAR →
  • high

    Cash and cash equivalents fell to $0.1M as of Sep 30, 2025; going-concern doubt persists and accumulated deficit rose from $117.0M (Jun 2025) to $269.6M (Sep 2025), reflecting the SPAC merger and ongoing operations.

    MD&A: Liquidity verify on EDGAR →
  • high

    Second Phase 3 clinical study for SP-102 initiated in Sep 2025, advancing the confirmatory trial typically required for FDA approval beyond the single pivotal study completed in Mar 2022.

    MD&A: Clinical Development verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (FRVO 10-Q) is open in full — no account needed.

Partner

Trade SMNR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · Jun 26, 2026 5:23 PM